This group successfully demonstrated the efficacy of the nonimmunosuppressive FTY720 analogue as an antitumor agent, which is evidenced by the fact that OSU-2S exhibited higher potency than FTY720 in suppressing HCC cell growth through PKCδ activation [11]. Here, PRKCD is linked to hepatocellular carcinoma.